In order to understand if there is other unknown side effect during the clinical trail, the PMS (Post-Marketing Study) will be conducted to learn more treatment experiences on patients, and collect their information for further study.
No. 9 of IRPMA COP Benchmarks regulates that all PMS shall go through JIRB, IRB or Ethics Committee and must be registered on the website of IRPMA PMS registry system. It is to ensure the studies conducted on patients have been approved by JIRB, IRB and protect patient’s right of privacy. The public can also get the information and objective of the PMS through the registry system.

Company Name	Title of Study	Update Date
GSK	A Phase IV, Prospective, Non-Interventional Cohort Study of Fostemsavir Based Regimen In Heavily Treatment Experienced Patient With Hiv-1 Infection In Taiwan	2023-05-24
AbbVie Biopharmaceuticals GmbH	Prospective Observational Cohort study of patients with moderate to severe chronic plaque psoriasis in Taiwan	2023-03-24
Gilead Sciences Hong Kong Ltd. Taiwan Branch	A Post-Authorization Study to Evaluate Safety and Clinical Outcomes in COVID-19 Patients Treated with Veklury® (Remdesivir) in Taiwan	2023-01-06
Gilead Sciences Hong Kong Limited, Taiwan Branch	Multi-country, non-interventional, cohort study of the effectiveness, safety, adherence, and health-related quality of life in HIV-1 infected adult patients receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Asia.	2023-01-06
Bayer Taiwan Co., Ltd.	Observational study evaluating the physical activity in a subset of damoctocog alfa pegol treated Hemophilia A patients who are enrolled in the HEM-POWR study.	2022-11-29
Bayer Taiwan Co., Ltd.	Observational Study Evaluating Effectiveness and Safety of Real-World Treatment with Damoctocog alfa pegol in Previously Treated Patients with Hemophilia A	2022-07-28
Bayer Taiwan Co., Ltd.	XATOC – Xarelto + Acetylsalicylic Acid: Treatment patterns and Outcomes across the disease Continuum in patients with CAD and/or PAD	2022-07-20
Bayer Taiwan Co., Ltd.	RAPIT/ Safety and Effectiveness of Xofigo® (Radium-223 dichloride) in Routine Clinical Practice Settings in Taiwan)	2022-07-07
Bayer Taiwan Co., Ltd.	XARETO / Xarelto® for the prevention of stroke and non-central nervous systemic embolism in non-valvular atrial fibrillation with REnal impairment in Taiwanese population.	2022-06-28
Pfizer	A Phase 4, Open-Label, Randomized study of two Inotuzumab ozogamicin dose levels in adult patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia eligible for Hematopoietic Stem cell Transplantation and who have Risk factor(s) for veno-occlusive Disease.	2022-01-20